Introducing XDEMVY™

Now FDA approved

We’re excited to announce that XDEMVY™ is now approved for Demodex blepharitis. Formerly known as TP-03, XDEMVY is the first and only FDA-approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.

Important Safety Information:
Most common side effects: Most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please see full Important Safety Information at XDEMVY.com.

  • If you are an eye care provider looking for product information, visit XDEMVYHCP.com
  • If you are a patient, visit XDEMVY.com

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

Opt-in
This field is for validation purposes and should be left unchanged.